1513A>C Polymorphism in the P2X7 Receptor Gene in Patients with Papillary Thyroid Cancer: Correlation with Histological Variants and Clinical Parameters
Open Access
- 1 February 2009
- journal article
- research article
- Published by The Endocrine Society in Journal of Clinical Endocrinology & Metabolism
- Vol. 94 (2) , 695-698
- https://doi.org/10.1210/jc.2008-1322
Abstract
Introduction: The modulation of the purinergic receptor P2X7 may be implicated in human carcinogenesis. The 1513A>C and 489C>T polymorphisms of P2X7R gene induce loss of function and gain of function, respectively. Aim: The aim of the study was to assess the frequency of both 1513A>C and 489C>T polymorphisms in patients with papillary thyroid carcinoma (PTC) and to evaluate the possible association with clinical and histological features. Patients and Methods: P2X7R analysis was performed in lymphocytes from 121 PTC patients (100 women, 21 men; aged 43.4 ± 13.6 yr), 100 matched healthy subjects, and 80 patients with nodular goiter. Results: The minor allele frequency for 1513A>C polymorphism in PTC patients with the classical variant was similar to controls (0.21 and 0.20, respectively), whereas it resulted in a significant increase in patients with the follicular variant (0.36; P = 0.01 vs. classical variant, and P = 0.005 vs. controls). In detail, 13.6% of patients with PTC follicular variant were homozygous for the 1513C allele, compared to 2.6% of patients with the classical variant and 2% of controls. Moreover, a positive relationship between 1513A>C polymorphism and either cancer diameter (Rho = 0.22; P = 0.02) or TNM stage (Rho = 0.38; P < 0.001) was found. No significant difference in the genotype frequency of 489C>T polymorphism between PTC patients and healthy controls was observed (0.42 and 0.47, respectively). Conclusions: Our data show, for the first time, a strong association between 1513A>C polymorphism of P2X7R gene and the follicular variant of PTC. Further studies are needed to confirm the possible role of this polymorphism as a novel clinical marker of PTC follicular variant and its usefulness in selecting patients with different clinical outcome.Keywords
This publication has 19 references indexed in Scilit:
- Increased P2X7 Receptor Expression and Function in Thyroid Papillary Cancer: A New Potential Marker of the Disease?Endocrinology, 2007
- The P2X7 Receptor: A Key Player in IL-1 Processing and ReleaseThe Journal of Immunology, 2006
- A His-155 to Tyr Polymorphism Confers Gain-of-Function to the Human P2X7 Receptor of Human Leukemic LymphocytesThe Journal of Immunology, 2005
- Extracellular Adenosine 5′-Triphosphate Modulates Interleukin-6 Production by Human Thyrocytes through Functional Purinergic P2 ReceptorsEndocrinology, 2005
- BRAFV599EMutation Is the Leading Genetic Event in Adult Sporadic Papillary Thyroid CarcinomasJournal of Clinical Endocrinology & Metabolism, 2004
- Early prostate cancer detected using expression of non‐functional cytolytic P2X7 receptorsHistopathology, 2004
- Differentiation between Cancerous and Normal Hyperplastic Lobules in Breast LesionsBreast Cancer Research and Treatment, 2004
- Expression of Purinergic Receptors in Non-melanoma Skin Cancers and Their Functional Roles in A431 CellsJournal of Investigative Dermatology, 2003
- A loss-of-function polymorphic mutation in the cytolytic P2X7 receptor gene and chronic lymphocytic leukaemia: a molecular studyThe Lancet, 2002
- A Glu-496 to Ala Polymorphism Leads to Loss of Function of the Human P2X7 ReceptorJournal of Biological Chemistry, 2001